Table 3 Treatment effect of immune checkpoint inhibitors after pemetrexed treatment failure
| Efficacy |
Long-term administration ( n = 11) |
Intermediate-term administration ( n = 16) |
Short-term administration ( n = 55) |
|---|---|---|---|
| Cycles | 6.1 ± 8.5 | 5.6 ± 3.2 | 6.2 ± 8.3 |
| PFS (month) | 5.5 ± 6.9 | 3.8 ± 2.7 | 3.4 ± 4.4 |